Evaluating the drug-target relationship between thymidylate synthase expression and tumor response to 5-fluorouracil: Is it time to move forward?

Shayna L. Showalter, Timothy N. Showalter, Agnes Witkiewicz, Robert Havens, Eugene P. Kennedy, Tomas Hucl, Scott E. Kern, Charles J. Yeo, Jonathan R. Brody

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Thymidylate synthase is a target of 5-fluoruracil, a pyrimidine analog used to treat gastrointestinal and other cancers. The 5-fluorouracil metabolite, fluoro-deoxyuridine monophosphate, forms a ternary complex with thymidylate synthase and 5,10-methylene tetrahydrofolate. The purpose of this study was to evaluate the time-honored connection between thymidylate synthase and 5-fluorouracil. From our literature search spanning reports from 1995 to 2007 published in journals having an impact factor greater than 2, we stratified the tumors within each article, according to low versus high thymidylate synthase expression. These groups were subdivided into responders, stable disease or disease progression. The relationship between thymidylate synthase expression and 5-fluorouracil response was analyzed for the overall group, as well as for subsets. Overall, the literature supported an approximately 2-fold inverse relationship between thymidylate synthase expression and response to 5-fluoruracil. We found no change in the trend for a relationship between thymidylate synthase and 5-fluorouracil when the literature was stratified by date of publication, impact factor of the journal in which the report was published, or substrate (mRNA versus protein) for measuring thymidylate synthase expression. Of note, there is no significant change in the trend when comparing 5-fluorouracil treatment alone or in combination with leucovorin. We found a decline of this trend when certain chemotherapeutics were used in combination with 5-fluorouracil. In sum, the connection between thymidylate synthase expression and patient response to 5-fluorouracil does not satisfy expectations for an effective drug-target relationship; and thus, studies of the thymidylate synthase tandem repeat status might only be clinically valuable in regards to patient toxicity. Thus, we question the reliability of thymidylate synthase expression as a clinical predictor of 5-fluorouracil response. Future research could perhaps be directed towards alternate targets and metabolites of 5-fluorouracil, in an effort to find a clinically relevant biomarker panel for response and to optimize fluoropyrimidine-based therapy.

Original languageEnglish (US)
Pages (from-to)986-994
Number of pages9
JournalCancer Biology and Therapy
Volume7
Issue number7
StatePublished - Jul 2008

Fingerprint

Thymidylate Synthase
Fluorouracil
Pharmaceutical Preparations
Neoplasms
Journal Impact Factor
Deoxyuridine
Tandem Repeat Sequences
Gastrointestinal Neoplasms
Leucovorin
Disease Progression
Publications
Biomarkers

Keywords

  • 5-fluorouracil
  • Chemotherapeutic resistance
  • Clinical response
  • Pharamocogenetic window
  • Pharmacogenomics
  • Resistance
  • Sensitivity
  • Thymidylate synthase

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Evaluating the drug-target relationship between thymidylate synthase expression and tumor response to 5-fluorouracil : Is it time to move forward? / Showalter, Shayna L.; Showalter, Timothy N.; Witkiewicz, Agnes; Havens, Robert; Kennedy, Eugene P.; Hucl, Tomas; Kern, Scott E.; Yeo, Charles J.; Brody, Jonathan R.

In: Cancer Biology and Therapy, Vol. 7, No. 7, 07.2008, p. 986-994.

Research output: Contribution to journalArticle

Showalter, SL, Showalter, TN, Witkiewicz, A, Havens, R, Kennedy, EP, Hucl, T, Kern, SE, Yeo, CJ & Brody, JR 2008, 'Evaluating the drug-target relationship between thymidylate synthase expression and tumor response to 5-fluorouracil: Is it time to move forward?', Cancer Biology and Therapy, vol. 7, no. 7, pp. 986-994.
Showalter, Shayna L. ; Showalter, Timothy N. ; Witkiewicz, Agnes ; Havens, Robert ; Kennedy, Eugene P. ; Hucl, Tomas ; Kern, Scott E. ; Yeo, Charles J. ; Brody, Jonathan R. / Evaluating the drug-target relationship between thymidylate synthase expression and tumor response to 5-fluorouracil : Is it time to move forward?. In: Cancer Biology and Therapy. 2008 ; Vol. 7, No. 7. pp. 986-994.
@article{c44692dca99844749244ab96db6ada40,
title = "Evaluating the drug-target relationship between thymidylate synthase expression and tumor response to 5-fluorouracil: Is it time to move forward?",
abstract = "Thymidylate synthase is a target of 5-fluoruracil, a pyrimidine analog used to treat gastrointestinal and other cancers. The 5-fluorouracil metabolite, fluoro-deoxyuridine monophosphate, forms a ternary complex with thymidylate synthase and 5,10-methylene tetrahydrofolate. The purpose of this study was to evaluate the time-honored connection between thymidylate synthase and 5-fluorouracil. From our literature search spanning reports from 1995 to 2007 published in journals having an impact factor greater than 2, we stratified the tumors within each article, according to low versus high thymidylate synthase expression. These groups were subdivided into responders, stable disease or disease progression. The relationship between thymidylate synthase expression and 5-fluorouracil response was analyzed for the overall group, as well as for subsets. Overall, the literature supported an approximately 2-fold inverse relationship between thymidylate synthase expression and response to 5-fluoruracil. We found no change in the trend for a relationship between thymidylate synthase and 5-fluorouracil when the literature was stratified by date of publication, impact factor of the journal in which the report was published, or substrate (mRNA versus protein) for measuring thymidylate synthase expression. Of note, there is no significant change in the trend when comparing 5-fluorouracil treatment alone or in combination with leucovorin. We found a decline of this trend when certain chemotherapeutics were used in combination with 5-fluorouracil. In sum, the connection between thymidylate synthase expression and patient response to 5-fluorouracil does not satisfy expectations for an effective drug-target relationship; and thus, studies of the thymidylate synthase tandem repeat status might only be clinically valuable in regards to patient toxicity. Thus, we question the reliability of thymidylate synthase expression as a clinical predictor of 5-fluorouracil response. Future research could perhaps be directed towards alternate targets and metabolites of 5-fluorouracil, in an effort to find a clinically relevant biomarker panel for response and to optimize fluoropyrimidine-based therapy.",
keywords = "5-fluorouracil, Chemotherapeutic resistance, Clinical response, Pharamocogenetic window, Pharmacogenomics, Resistance, Sensitivity, Thymidylate synthase",
author = "Showalter, {Shayna L.} and Showalter, {Timothy N.} and Agnes Witkiewicz and Robert Havens and Kennedy, {Eugene P.} and Tomas Hucl and Kern, {Scott E.} and Yeo, {Charles J.} and Brody, {Jonathan R.}",
year = "2008",
month = "7",
language = "English (US)",
volume = "7",
pages = "986--994",
journal = "Cancer Biology and Therapy",
issn = "1538-4047",
publisher = "Landes Bioscience",
number = "7",

}

TY - JOUR

T1 - Evaluating the drug-target relationship between thymidylate synthase expression and tumor response to 5-fluorouracil

T2 - Is it time to move forward?

AU - Showalter, Shayna L.

AU - Showalter, Timothy N.

AU - Witkiewicz, Agnes

AU - Havens, Robert

AU - Kennedy, Eugene P.

AU - Hucl, Tomas

AU - Kern, Scott E.

AU - Yeo, Charles J.

AU - Brody, Jonathan R.

PY - 2008/7

Y1 - 2008/7

N2 - Thymidylate synthase is a target of 5-fluoruracil, a pyrimidine analog used to treat gastrointestinal and other cancers. The 5-fluorouracil metabolite, fluoro-deoxyuridine monophosphate, forms a ternary complex with thymidylate synthase and 5,10-methylene tetrahydrofolate. The purpose of this study was to evaluate the time-honored connection between thymidylate synthase and 5-fluorouracil. From our literature search spanning reports from 1995 to 2007 published in journals having an impact factor greater than 2, we stratified the tumors within each article, according to low versus high thymidylate synthase expression. These groups were subdivided into responders, stable disease or disease progression. The relationship between thymidylate synthase expression and 5-fluorouracil response was analyzed for the overall group, as well as for subsets. Overall, the literature supported an approximately 2-fold inverse relationship between thymidylate synthase expression and response to 5-fluoruracil. We found no change in the trend for a relationship between thymidylate synthase and 5-fluorouracil when the literature was stratified by date of publication, impact factor of the journal in which the report was published, or substrate (mRNA versus protein) for measuring thymidylate synthase expression. Of note, there is no significant change in the trend when comparing 5-fluorouracil treatment alone or in combination with leucovorin. We found a decline of this trend when certain chemotherapeutics were used in combination with 5-fluorouracil. In sum, the connection between thymidylate synthase expression and patient response to 5-fluorouracil does not satisfy expectations for an effective drug-target relationship; and thus, studies of the thymidylate synthase tandem repeat status might only be clinically valuable in regards to patient toxicity. Thus, we question the reliability of thymidylate synthase expression as a clinical predictor of 5-fluorouracil response. Future research could perhaps be directed towards alternate targets and metabolites of 5-fluorouracil, in an effort to find a clinically relevant biomarker panel for response and to optimize fluoropyrimidine-based therapy.

AB - Thymidylate synthase is a target of 5-fluoruracil, a pyrimidine analog used to treat gastrointestinal and other cancers. The 5-fluorouracil metabolite, fluoro-deoxyuridine monophosphate, forms a ternary complex with thymidylate synthase and 5,10-methylene tetrahydrofolate. The purpose of this study was to evaluate the time-honored connection between thymidylate synthase and 5-fluorouracil. From our literature search spanning reports from 1995 to 2007 published in journals having an impact factor greater than 2, we stratified the tumors within each article, according to low versus high thymidylate synthase expression. These groups were subdivided into responders, stable disease or disease progression. The relationship between thymidylate synthase expression and 5-fluorouracil response was analyzed for the overall group, as well as for subsets. Overall, the literature supported an approximately 2-fold inverse relationship between thymidylate synthase expression and response to 5-fluoruracil. We found no change in the trend for a relationship between thymidylate synthase and 5-fluorouracil when the literature was stratified by date of publication, impact factor of the journal in which the report was published, or substrate (mRNA versus protein) for measuring thymidylate synthase expression. Of note, there is no significant change in the trend when comparing 5-fluorouracil treatment alone or in combination with leucovorin. We found a decline of this trend when certain chemotherapeutics were used in combination with 5-fluorouracil. In sum, the connection between thymidylate synthase expression and patient response to 5-fluorouracil does not satisfy expectations for an effective drug-target relationship; and thus, studies of the thymidylate synthase tandem repeat status might only be clinically valuable in regards to patient toxicity. Thus, we question the reliability of thymidylate synthase expression as a clinical predictor of 5-fluorouracil response. Future research could perhaps be directed towards alternate targets and metabolites of 5-fluorouracil, in an effort to find a clinically relevant biomarker panel for response and to optimize fluoropyrimidine-based therapy.

KW - 5-fluorouracil

KW - Chemotherapeutic resistance

KW - Clinical response

KW - Pharamocogenetic window

KW - Pharmacogenomics

KW - Resistance

KW - Sensitivity

KW - Thymidylate synthase

UR - http://www.scopus.com/inward/record.url?scp=47949110995&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47949110995&partnerID=8YFLogxK

M3 - Article

C2 - 18443433

AN - SCOPUS:47949110995

VL - 7

SP - 986

EP - 994

JO - Cancer Biology and Therapy

JF - Cancer Biology and Therapy

SN - 1538-4047

IS - 7

ER -